Summary

The veterinary vaccines market is projected to reach USD 13.33 billion by 2029, from USD 9.39 billion in 2024, at a CAGR of 6.1%.” during the forecast period.

The growing awareness of animal health, along with the rising pet population and pet ownership, is driving the adoption of veterinary vaccines. Government initiatives aimed at improving animal health and the increasing uptake of pet insurance policies are also contributing to this trend. In major markets like North America and Europe, many pet owners are purchasing pet insurance due to the significant rise in pet care spending in recent years. Additionally, the focus on developing new and advanced vaccine products, combined with the growing adoption of veterinary vaccines in emerging economies, is expected to further support market growth. However, the high costs associated with vaccines may pose a challenge to the veterinary vaccines market's expansion.

“The livestock vaccines segment of veterinary vaccines market to register highest share during the forecast period.”

Based on type, the livestock vaccines segment accounted for the largest share. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving productivity. Additionally, government regulations, rising awareness about animal health, and growing demand for safer, disease-free food products are driving the adoption of livestock vaccines, further contributing to their dominant share in the market.





“The intramuscular segment to capture the largest market share of veterinary vaccines market.”

Based on route of administration, intramuscular vaccines hold a higher share in the veterinary vaccines market due to their effectiveness and widespread use. Compared to conventional methods of administration like subcutaneous or oral vaccines, this kind of vaccine is delivered directly into the muscle, enabling a faster and more powerful immune response. Because of their ability to produce long-lasting immunity, intramuscular vaccines are frequently used to treat a range of conditions, including bacterial, viral, and parasite infections. The increased market share of intramuscular vaccines is partly a result of their shown efficacy, simplicity of use, and veterinarians' inclination for this approach in both individual pet care and large-scale farming.


“Asia pacific accounted for the fastest growing region of the veterinary vaccines market by region.”
The global veterinary vaccines market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing market for veterinary vaccines. The increased ownership of pets is a major factor driving the need for veterinary care and vaccinations, particularly in economies like China, India, and Japan. Pet owners are also being encouraged to invest in vaccinations as a result of the region's increasing awareness of animal health and preventative measures. Growing focus on livestock health, better veterinary facilities, and economic expansion all contribute significantly to the market's growth. Governments and organizations have backed animal health initiatives, and more consumers are looking for improved pet healthcare as disposable incomes rise. The Asia Pacific region is becoming a significant growth engine for the veterinary vaccines market due to this confluence of variables.


A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3– 25%
• By Designation: Directors–25%, Managers–50% and Others–25%
• By Region: North America–35%, Europe–30%, Asia Pacific–15% and RoW–20%

The major players operating in the veterinary vaccines market market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogénesis Bagó (Argentina), Tianjin Ringpu BioTechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V.(Netherlands).

Research Coverage

This report studies the veterinary vaccines market based on type, disease, technology, route of administration and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Analysis of Key divers (increased companion animal population and pet ownership, growing incidence of infectious disease, government initiatives to improve animal health), restraints (high cost associated with vaccines), Opportunities (emerging markets, technological advancement and developments) , Challenge (limited awareness and shortage of veterinarians, stringent regulatory requirements)
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the veterinary vaccines market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the veterinary vaccines market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the veterinary vaccines market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.3 STUDY SCOPE 34
1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD 34
1.3.2 INCLUSIONS & EXCLUSIONS 35
1.3.3 YEARS CONSIDERED 36
1.3.4 CURRENCY CONSIDERED 36
1.4 STAKEHOLDERS 36
1.5 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 39
2.1.1.1 Key secondary sources 39
2.1.1.2 Key data from secondary sources 40
2.1.2 PRIMARY DATA 40
2.1.2.1 Key primary sources 40
2.1.2.2 Objectives of primary research 41
2.1.2.3 Key data from primary sources 41
2.1.2.4 Key industry insights 42
2.1.2.5 Breakdown of primaries 42
2.2 MARKET SIZE ESTIMATION 44
2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 44
2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 46
2.2.3 TOP-DOWN APPROACH 48
2.3 DATA TRIANGULATION 49
2.4 MARKET SHARE ANALYSIS 50
2.5 STUDY ASSUMPTIONS 50
2.6 RISK ASSESSMENT 50
2.7 RESEARCH LIMITATIONS 51
2.7.1 METHODOLOGY-RELATED LIMITATIONS 51
2.7.2 SCOPE-RELATED LIMITATIONS 51
3 EXECUTIVE SUMMARY 52

4 PREMIUM INSIGHTS 57
4.1 VETERINARY VACCINES MARKET OVERVIEW 57
4.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023) 58
4.3 VETERINARY VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Rise in companion animal population and pet ownership 61
5.2.1.2 Increasing incidence of infectious zoonotic diseases 62
5.2.1.3 Favorable initiatives by government agencies and
animal associations 62
5.2.1.4 Growing demand for animal-derived food products 63
5.2.1.5 Increased adoption of pet insurance and high
animal health expenditure 65
5.2.2 RESTRAINTS 66
5.2.2.1 High cost of vaccine development 66
5.2.3 OPPORTUNITIES 66
5.2.3.1 Technological advancements for veterinary vaccine development 66
5.2.3.2 Untapped growth potential in emerging economies 67
5.2.4 CHALLENGES 67
5.2.4.1 Limited awareness about animal vaccines and shortage of trained veterinarians in low-income countries 67
5.2.4.2 Stringent regulatory requirements for licensing veterinary vaccines 68
5.3 INDUSTRY TRENDS 68
5.4 TECHNOLOGY ANALYSIS 69
5.4.1 KEY TECHNOLOGIES 69
5.4.1.1 Recombinant DNA technology 69
5.4.1.2 mRNA-based vaccines 69
5.4.2 COMPLEMENTARY TECHNOLOGIES 70
5.4.2.1 Vaccine adjuvant technology 70
5.4.2.2 Needle-free and microneedle technology 70
5.4.3 ADJACENT TECHNOLOGIES 70
5.4.3.1 Genome editing technology 70
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 71
5.6 SUPPLY CHAIN ANALYSIS 71
5.7 VALUE CHAIN ANALYSIS 73
5.8 TRADE ANALYSIS 74
5.8.1 IMPORT DATA FOR HS CODE 300242 74
5.8.2 EXPORT DATA FOR HS CODE 300230 75

5.9 PORTER’S FIVE FORCES ANALYSIS 75
5.9.1 THREAT OF NEW ENTRANTS 77
5.9.2 THREAT OF SUBSTITUTES 77
5.9.3 BARGAINING POWER OF SUPPLIERS 77
5.9.4 BARGAINING POWER OF BUYERS 77
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.10 KEY STAKEHOLDERS & BUYING CRITERIA 78
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 78
5.10.2 KEY BUYING CRITERIA 79
5.11 REGULATORY ANALYSIS 80
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
5.11.2 REGULATORY FRAMEWORK 83
5.11.2.1 North America 84
5.11.2.1.1 US 84
5.11.2.2 Europe 84
5.11.2.3 Rest of the World 85
5.11.2.3.1 China 85
5.11.2.3.2 Brazil 85
5.11.2.3.3 Australia 85
5.12 PATENT ANALYSIS 86
5.12.1 JURISDICTION AND TOP APPLICANT ANALYSIS 86
5.13 PRICING ANALYSIS 89
5.13.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES,
BY KEY PLAYER, 2021–2023 89
5.13.2 AVERAGE SELLING PRICE TREND, BY REGION, 2021–2023 91
5.14 KEY CONFERENCES & EVENTS, 2024–2026 92
5.15 ECOSYSTEM ANALYSIS 94
5.16 CASE STUDY ANALYSIS 95
5.17 REIMBURSEMENT ANALYSIS 97
5.18 UNMET NEEDS/END-USER EXPECTATIONS 97
5.19 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET 98
5.20 INVESTMENT & FUNDING SCENARIO 98
5.21 PIPELINE ANALYSIS 99
6 VETERINARY VACCINES MARKET, BY TYPE 101
6.1 INTRODUCTION 102
6.2 LIVESTOCK VACCINES 103
6.2.1 BOVINE VACCINES 105
6.2.1.1 Increasing demand for meat and milk to drive market 105
6.2.2 SMALL RUMINANT VACCINES 107
6.2.2.1 Increased livestock population and favorable government initiatives to propel market growth 107
6.3 PORCINE VACCINES 109
6.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO
SUPPORT MARKET GROWTH 109
6.4 POULTRY VACCINES 111
6.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH 111
6.5 COMPANION ANIMAL VACCINES 113
6.5.1 CANINE VACCINES 115
6.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth 115
6.5.2 FELINE VACCINES 117
6.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth 117
6.6 AQUACULTURE VACCINES 119
6.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO
FUEL MARKET GROWTH 119
6.7 OTHER VETERINARY VACCINES 120
7 VETERINARY VACCINES MARKET, BY DISEASE 122
7.1 INTRODUCTION 123
7.2 LIVESTOCK DISEASES 123
7.2.1 BOVINE DISEASES 126
7.2.1.1 Favorable government programs and increased awareness about animal health in emerging economies to aid market growth 126
7.2.2 SMALL RUMINANT DISEASES 128
7.2.2.1 New vaccine formulations and improved delivery methods to propel vaccine demand for small ruminants 128
7.3 PORCINE DISEASES 130
7.3.1 INCREASED FOCUS ON LARGE-SCALE INDUSTRIAL BREEDING OF
PIGS TO AID MARKET GROWTH 130
7.4 POULTRY DISEASES 132
7.4.1 ONGOING RISK OF AVIAN INFLUENZA OUTBREAKS TO SPUR
NEED FOR POULTRY VACCINES 132
7.5 COMPANION ANIMAL DISEASES 134
7.5.1 CANINE DISEASES 136
7.5.1.1 Rise in pet ownership in emerging economies to boost market growth 136
7.5.2 FELINE DISEASES 138
7.5.2.1 Rise in cat population in urban areas to drive demand for feline disease management programs 138
7.6 AQUACULTURE DISEASES 140
7.6.1 NEED FOR PREVENTIVE HEALTHCARE AND BIOSECURITY TO
SUPPORT MARKET GROWTH 140
7.7 OTHER VETERINARY DISEASES 142

8 VETERINARY VACCINES MARKET, BY TECHNOLOGY 144
8.1 INTRODUCTION 145
8.2 LIVE ATTENUATED VACCINES 145
8.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO
SUPPORT MARKET GROWTH 145
8.3 INACTIVATED VACCINES 147
8.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING
PATHOGENS TO DRIVE MARKET 147
8.4 TOXOID VACCINES 149
8.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS 149
8.5 RECOMBINANT VACCINES 151
8.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION 151
8.6 OTHER VACCINE TECHNOLOGIES 153
9 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 155
9.1 INTRODUCTION 156
9.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 158
9.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH 158
9.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 161
9.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH 161
9.4 ORAL ROUTE OF ADMINISTRATION 163
9.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH 163
9.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION 165
9.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION 165
9.6 INTRAOCULAR ROUTE OF ADMINISTRATION 167
9.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH 167
9.7 OTHER ROUTES OF ADMINISTRATION 169
10 VETERINARY VACCINES MARKET, BY END USER 171
10.1 INTRODUCTION 172
10.2 VETERINARY HOSPITALS 172
10.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET 172
10.3 VETERINARY CLINICS 174
10.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO
SPUR MARKET GROWTH 174
10.4 OTHER END USERS 176
11 VETERINARY VACCINES MARKET, BY REGION 177
11.1 INTRODUCTION 178
11.2 ASIA PACIFIC 182
11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 187
11.2.2 CHINA 189
11.2.2.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market 189
11.2.3 JAPAN 193
11.2.3.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth 193
11.2.4 INDIA 197
11.2.4.1 Growth in poultry industry and high demand for dairy products to augment market growth 197
11.2.5 AUSTRALIA 202
11.2.5.1 Increase in per capita income and rise in meat consumption to
aid market growth 202
11.2.6 SOUTH KOREA 206
11.2.6.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth 206
11.2.7 NEW ZEALAND 210
11.2.7.1 Favorable government initiatives and increased incidence of livestock diseases to boost market growth 210
11.2.8 REST OF ASIA PACIFIC 214
11.3 NORTH AMERICA 218
11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 223
11.3.2 US 224
11.3.2.1 US to dominate North American veterinary vaccines market
during forecast period 224
11.3.3 CANADA 228
11.3.3.1 Rising pet ownership and increasing chicken consumption to
drive demand for veterinary vaccines 228
11.4 EUROPE 232
11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE 237
11.4.2 GERMANY 238
11.4.2.1 Increased poultry consumption and high pet healthcare expenditure to drive market 238
11.4.3 UK 242
11.4.3.1 Rising adoption of pets to augment market growth 242
11.4.4 FRANCE 246
11.4.4.1 Rising companion animal and livestock population to
boost market growth 246
11.4.5 ITALY 250
11.4.5.1 Better availability of pet products through large-scale outlets to augment market growth 250

11.4.6 SPAIN 254
11.4.6.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market 254
11.4.7 NETHERLANDS 258
11.4.7.1 High demand for meat and increased pressure on sustainable farming practices to fuel market growth 258
11.4.8 REST OF EUROPE 262
11.5 LATIN AMERICA 266
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 270
11.5.2 BRAZIL 271
11.5.2.1 Well-established livestock industry to promote market growth 271
11.5.3 MEXICO 275
11.5.3.1 Focus on pork and poultry meat production to fuel market growth 275
11.5.4 REST OF LATIN AMERICA 279
11.6 MIDDLE EAST & AFRICA 282
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 287
11.6.2 GCC COUNTRIES 288
11.6.2.1 Kingdom of Saudi Arabia 292
11.6.2.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth 292
11.6.2.2 UAE 296
11.6.2.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture 296
11.6.2.3 Rest of GCC countries 300
11.6.3 REST OF MIDDLE EAST & AFRICA 304
12 COMPETITIVE LANDSCAPE 308
12.1 INTRODUCTION 308
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 308
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 308
12.3 REVENUE ANALYSIS, 2019–2023 310
12.4 MARKET SHARE ANALYSIS, 2023 311
12.4.1 RANKING OF KEY MARKET PLAYERS, 2O23 313
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 314
12.5.1 STARS 314
12.5.2 EMERGING LEADERS 314
12.5.3 PERVASIVE PLAYERS 314
12.5.4 PARTICIPANTS 314
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 316
12.5.5.1 Company footprint 316
12.5.5.2 Region footprint 317
12.5.5.3 Type footprint 318

12.5.5.4 Disease footprint 319
12.5.5.5 Technology footprint 320
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 321
12.6.1 PROGRESSIVE COMPANIES 321
12.6.2 RESPONSIVE COMPANIES 321
12.6.3 DYNAMIC COMPANIES 321
12.6.4 STARTING BLOCKS 321
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 323
12.7 BRAND/PRODUCT COMPARISON 324
12.8 R&D EXPENDITURE OF KEY PLAYERS 325
12.9 COMPANY VALUATION & FINANCIAL METRICS 325
12.9.1 FINANCIAL METRICS 325
12.9.2 COMPANY VALUATION 326
12.10 COMPETITIVE SCENARIO 326
12.10.1 PRODUCT LAUNCHES & APPROVALS 326
12.10.2 DEALS 327
12.10.3 EXPANSIONS 328
12.10.4 OTHER DEVELOPMENTS 328
13 COMPANY PROFILES 329
13.1 KEY PLAYERS 329
13.1.1 MERCK & CO., INC. 329
13.1.1.1 Business overview 329
13.1.1.2 Products offered 330
13.1.1.3 Recent developments 333
13.1.1.3.1 Product launches & approvals 333
13.1.1.3.2 Deals 334
13.1.1.3.3 Expansions 334
13.1.1.3.4 Other developments 335
13.1.1.4 MnM view 335
13.1.1.4.1 Right to win 335
13.1.1.4.2 Strategic choices 335
13.1.1.4.3 Weaknesses & competitive threats 335
13.1.2 ZOETIS 336
13.1.2.1 Business overview 336
13.1.2.2 Products offered 337
13.1.2.3 Recent developments 339
13.1.2.3.1 Product launches 339
13.1.2.3.2 Deals 339
13.1.2.3.3 Expansions 339
13.1.2.3.4 Other developments 340

13.1.2.4 MnM view 340
13.1.2.4.1 Right to win 340
13.1.2.4.2 Strategic choices 340
13.1.2.4.3 Weaknesses & competitive threats 340
13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 341
13.1.3.1 Business overview 341
13.1.3.2 Products offered 342
13.1.3.3 Recent developments 343
13.1.3.3.1 Product launches 343
13.1.3.3.2 Expansions 344
13.1.3.4 MnM view 344
13.1.3.4.1 Right to win 344
13.1.3.4.2 Strategic choices 344
13.1.3.4.3 Weaknesses & competitive threats 345
13.1.4 ELANCO 346
13.1.4.1 Business overview 346
13.1.4.2 Products offered 348
13.1.4.3 Recent developments 349
13.1.4.3.1 Deals 349
13.1.5 CEVA 350
13.1.5.1 Business overview 350
13.1.5.2 Products offered 350
13.1.5.3 Recent developments 352
13.1.5.3.1 Deals 352
13.1.5.3.2 Expansions 353
13.1.6 VIRBAC 354
13.1.6.1 Business overview 354
13.1.6.2 Products offered 355
13.1.6.3 Recent developments 356
13.1.6.3.1 Product launches 356
13.1.6.3.2 Deals 357
13.1.6.3.3 Expansions 357
13.1.6.3.4 Other developments 358
13.1.7 PHIBRO ANIMAL HEALTH CORPORATION 359
13.1.7.1 Business overview 359
13.1.7.2 Products offered 360
13.1.8 HESTER BIOSCIENCES LIMITED 362
13.1.8.1 Business overview 362
13.1.8.2 Products offered 363
13.1.8.3 Recent developments 365
13.1.8.3.1 Deals 365

13.1.9 NEOGEN CORPORATION 366
13.1.9.1 Business overview 366
13.1.9.2 Products offered 367
13.1.9.3 Recent developments 368
13.1.9.3.1 Deals 368
13.1.10 HIPRA 369
13.1.10.1 Business overview 369
13.1.10.2 Products offered 369
13.1.10.3 Recent developments 372
13.1.10.3.1 Product launches 372
13.1.11 BIOGÉNESIS BAGÓ 373
13.1.11.1 Business overview 373
13.1.11.2 Products offered 373
13.1.11.3 Recent developments 374
13.1.11.3.1 Expansions 374
13.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. 375
13.1.12.1 Business overview 375
13.1.12.2 Products offered 376
13.1.12.3 Recent developments 378
13.1.12.3.1 Deals 378
13.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. 379
13.1.13.1 Business overview 379
13.1.13.2 Products offered 379
13.1.14 JINYU BIO-TECHNOLOGY CO., LTD. 381
13.1.14.1 Business overview 381
13.1.14.2 Products offered 382
13.1.14.3 Recent developments 384
13.1.14.3.1 Product approvals 384
13.1.15 VAXXINOVA INTERNATIONAL B.V. 385
13.1.15.1 Business overview 385
13.1.15.2 Products offered 386
13.1.15.3 Recent developments 387
13.1.15.3.1 Product approvals 387
13.1.15.3.2 Expansions 387
13.2 OTHER COMPANIES 388
13.2.1 ENDOVAC ANIMAL HEALTH 388
13.2.2 BRILLIANT BIO PHARMA 389
13.2.3 APTIMMUNE 390
13.2.4 INDIAN IMMUNOLOGICALS LTD. 391
13.2.5 TORIGEN PHARMACEUTICALS INC. 392
13.2.6 INTAS PHARMACEUTICALS LTD. 392
13.2.7 OUROFINO ANIMAL HEALTH 393
13.2.8 BIOVAC LTD. 394
13.2.9 LABORATOIRE LCV 395
13.2.10 KYORITSU SEIYAKU CORPORATION 396
14 APPENDIX 397
14.1 DISCUSSION GUIDE 397
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 403
14.3 CUSTOMIZATION OPTIONS 405
14.4 RELATED REPORTS 405
14.5 AUTHOR DETAILS 406